Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Zacks
在Zacks上打开
Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Avantor, Inc. (AVTR) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Avantor, Inc. is a member of the Medical sector. This group includes 916 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Avantor, Inc. is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for AVTR's full-year earnings has moved 0.8% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the most recent data, AVTR has returned 45.6% so far this year. At the same time, Medical stocks have gained an average of 8.3%. This means that Avantor, Inc. is outperforming the sector as a whole this year.

Another Medical stock, which has outperformed the sector so far this year, is Novartis (NVS). The stock has returned 16.9% year-to-date.

The consensus estimate for Novartis' current year EPS has increased 2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Looking more specifically, Avantor, Inc. belongs to the Medical Services industry, which includes 70 individual stocks and currently sits at #102 in the Zacks Industry Rank. On average, stocks in this group have gained 11.6% this year, meaning that AVTR is performing better in terms of year-to-date returns.

In contrast, Novartis falls under the Large Cap Pharmaceuticals industry. Currently, this industry has 11 stocks and is ranked #212. Since the beginning of the year, the industry has moved +22.5%.

Investors with an interest in Medical stocks should continue to track Avantor, Inc. and Novartis. These stocks will be looking to continue their solid performance.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Avantor, Inc. (AVTR): Free Stock Analysis Report
 
Novartis AG (NVS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research